Stem Cell Theranostics and CapellaBio launch collaboration on cardiotoxicity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and Kymab announced a partnership in immuno-oncology research.

The program will be conducted with MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation unit. The partnership will focus on developing novel human therapeutic antibodies to treat a variety of cancers using Kymab’s Kymouse antibody discovery platform. The agreement is for an initial period of five years.

The ORBIT platform is a centralized organization within MD Anderson, which focuses on translating discoveries into clinically relevant anti-cancer mAbs. ORBIT’s scientific directors are Jeffrey Molldrem, professor of the Department of Stem Cell Transplantation and Cellular Therapy, and Michael Curran, professor of the Department of Immunology.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login